Shaoqing Chen, Roche to Speak at Protein Kinases Meeting in Boston, May 30-31

Monrovia, California (PressExposure) March 16, 2012 -- Shaoqing Chen, Senior Scientist, Discovery Chemistry, Hoffmann-La Roche to give a Presentation on "Identification of Novel, Potent and Selective Polo-like Kinase 1 (PLK1) Inhibitors for Treatment of Cancer" at the 7th Protein Kinases in Drug Discovery Conference (May 30-31, 2012 in Boston, MA)

Identification of Novel, Potent and Selective Polo-like Kinase 1 (PLK1) Inhibitors for Treatment of Cancer

The Polo-like kinases (PLKs), members of the serine/threonine family of kinases, play a variety of roles in G2/M phase transition and have been identified as key regulators of cell mitosis. Inhibition of PLK1 kinase activity by a small molecule represents a novel approach to target mitosis and may be clearly differentiated from other mitosis-targeting agents on the market. PLK1 is a promising therapeutic target for cancer and several PLK1 inhibitors have shown promising results in phase I or II clinical trials. In this talk we report the discovery of a novel class of pyrimidodiazepinones as potent and selective ATP-competitive PLK1 inhibitors. The lead compound exhibits potent antiproliferative activity in a wide range of cancer cell lines, and shows strong antitumor activity in xenograft mouse models.

Dr. Chen will present his findings at the 7th Protein Kinases in Drug Discovery Conference in Boston, MA, to be held on May 30-31, 2012. Topics to be discussed at the event include:

Overcoming Challenges in Kinase Drug Development Trends in Drug Design - Structure/Selectivity/Pathway/Epigenetics Oncology Kinases & Inhibitor Candidates Other Kinases & Inhibitor Candidates

Top companies and experts in the field of Protein Kinases will come together to discuss their latest discoveries. Companies participating include ArQule, Avila, Beactica AB, Amgen, Bristol-Myers-Squibb, Eli Lilly, Pfizer, Roche, Merck and more!

Keynote & Featured Speakers Include:

Michael Yaffe, Professor, Biology & Biological Engineering, Massachusetts Institute of Technology

Nathanael Gray, Principal Investigator, Biological Chemistry & Molecular Pharmacology, Dana Farber Cancer Institute

Craig C Mello, Nobel Laureate & Distinguished Professor, Molecular Medicine, University of Massachusetts Medical School; HHMI

George Church, Professor, Genetics; Director, Center for Computational Genetics, Harvard Medical School

Steven Burrill, Chief Executive Officer, Burrill & Company

This 7th Protein Kinases in Drug Discovery conference is part of the Omics Evolution Summit which consists of five other conferences:

2nd Genomic & Proteomic Drug Discovery
2nd Next Generation Sequencing
Genome-wide Partnering and Dealmaking
2nd Epigentics in Drug Discovery
3rd RNAi Research and Development

To view the Program Agenda Click Here. For more information, please visit http://www.gtcbio.com

About GTCbio

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.


GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source: http://PressExposure.com/PR/GTCbio.html

Press Release Submitted On: March 16, 2012 at 1:45 am
This article has been viewed 83834 time(s).